You just read:

Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises In Sickle Cell Disease

News provided by

Hillhurst Biopharmaceuticals, Inc.

May 24, 2016, 15:41 ET